NASDAQ:ODT - Odonate Therapeutics Stock Price, Forecast & News

Odonate Therapeutics trades on the NASDAQ under the ticker symbol "ODT."

Odonate Therapeutics Inc (NASDAQ:ODT) released its earnings results on Thursday, February, 20th. The company reported ($0.91) EPS for the quarter, beating analysts' consensus estimates of ($1.02) by $0.11. View Odonate Therapeutics' Earnings History.

Odonate Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, April 23rd 2020. View Earnings Estimates for Odonate Therapeutics.

2 equities research analysts have issued 12-month price targets for Odonate Therapeutics' stock. Their forecasts range from $26.00 to $26.00. On average, they anticipate Odonate Therapeutics' stock price to reach $26.00 in the next year. This suggests that the stock has a possible downside of 23.9%. View Analyst Price Targets for Odonate Therapeutics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Odonate Therapeutics in the last year. There are currently 1 sell rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Odonate Therapeutics.

News articles about ODT stock have been trending somewhat positive on Saturday, InfoTrie reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Odonate Therapeutics earned a media sentiment score of 0.5 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Odonate Therapeutics.

Odonate Therapeutics saw a decline in short interest in the month of January. As of January 31st, there was short interest totalling 1,230,000 shares, a decline of 7.5% from the January 15th total of 1,330,000 shares. Based on an average daily volume of 103,500 shares, the short-interest ratio is presently 11.9 days. Approximately 4.2% of the company's shares are short sold. View Odonate Therapeutics' Current Options Chain.

Some companies that are related to Odonate Therapeutics include Evotec (EVTCY), Nektar Therapeutics (NKTR), Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals PLC- (GWPH), FibroGen (FGEN), Mirati Therapeutics (MRTX), Agios Pharmaceuticals (AGIO), Blueprint Medicines (BPMC), HUTCHISON CHINA/S (HCM), PTC Therapeutics (PTCT), Zai Lab (ZLAB), SAGE Therapeutics (SAGE), Ultragenyx Pharmaceutical (RARE), Emergent Biosolutions (EBS) and Alkermes (ALKS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Odonate Therapeutics investors own include Exelixis (EXEL), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Five Prime Therapeutics (FPRX), Nektar Therapeutics (NKTR), Progenics Pharmaceuticals (PGNX), TherapeuticsMD (TXMD), Bausch Health Companies (BHC) and Acorda Therapeutics (ACOR).

(ODT) raised $150 million in an initial public offering on Thursday, December 7th 2017. The company issued 5,900,000 shares at a price of $24.00-$27.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Cowen was co-manager.

Odonate Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (4.14%), Franklin Resources Inc. (3.71%), Driehaus Capital Management LLC (2.07%), State Street Corp (0.75%), Pictet Asset Management Ltd. (0.61%) and Geode Capital Management LLC (0.52%). Company insiders that own Odonate Therapeutics stock include Boxer Capital, Llc, Jeff L Vacirca and Kevin C Tang. View Institutional Ownership Trends for Odonate Therapeutics.

ODT stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Franklin Resources Inc., Oxford Asset Management LLP, Goldman Sachs Group Inc., California Public Employees Retirement System, Chartwell Investment Partners LLC, Spark Investment Management LLC and Bank of America Corp DE. View Insider Buying and Selling for Odonate Therapeutics.

ODT stock was acquired by a variety of institutional investors in the last quarter, including Driehaus Capital Management LLC, Pictet Asset Management Ltd., State Street Corp, Janus Henderson Group PLC, Virtus ETF Advisers LLC, AQR Capital Management LLC, UBS Group AG and Bank of New York Mellon Corp. Company insiders that have bought Odonate Therapeutics stock in the last two years include Boxer Capital, Llc, Jeff L Vacirca and Kevin C Tang. View Insider Buying and Selling for Odonate Therapeutics.

Shares of ODT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ODT stock can currently be purchased for approximately $34.15.

Odonate Therapeutics has a market capitalization of $1.10 billion. The company earns $-88,960,000.00 in net income (profit) each year or ($3.64) on an earnings per share basis. Odonate Therapeutics employs 117 workers across the globe.View Additional Information About Odonate Therapeutics.

The official website for Odonate Therapeutics is http://www.odonate.com/.

Odonate Therapeutics' mailing address is 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121. The company can be reached via phone at 858-731-8180 or via email at [email protected]